Condition: Recurrent Pancreatic Ductal Adenocarcinoma · Sponsor: UMC Utrecht
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on survival after recurrence in patients with isolated local pancreatic ductal adenocarcinoma (PDAC) recurrence. The most important secondary endpoint is quality of life. Other secondary endpoints are treatment response, acute and late toxicity, overall survival, progression-free survival, local progression-free survival, distant metastases free survival and reasons for non-eligibility or exclusion.
This description comes directly from the study's public registry record.
M. P.W. Intven, MD PhD · 0630866525 · m.intven@umcutrecht.nl
Always discuss trial participation with your own doctor first.
| Amsterdam University Medical Center, VUmc | Amsterdam, North Holland, Netherlands | Recruiting |
| Erasmus University Medical Center | Rotterdam, South Holland, Netherlands | Recruiting |
| University Medical Center Utrecht | Utrecht, Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04881487